Evidence map›Paper›PMID 38493481›Full record

ArticleBlood2024

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.

Marc Usart, Jan Stetka, Damien Luque Paz, Nils Hansen, Quentin Kimmerlin, Tiago Almeida Fonseca, Melissa Lock, Lucia Kubovcakova, Riikka Karjalainen, Hui Hao-Shen and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.Current hematologic malignancy reports · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Polycythaemia vera.Nature reviews. Disease primers · 2025
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Marc UsartDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0009-0002-4575-8029
Jan StetkaDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-4301-2856
Damien Luque PazUniversity of Angers, Nantes Université, Centre Hospitalier Universitaire Angers, INSERM, Centre National de la Recherche Scientifique, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Angers, France.ORCID 0000-0002-4523-675X
Nils HansenDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Quentin KimmerlinDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Tiago Almeida FonsecaDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Melissa LockDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Lucia KubovcakovaDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Riikka KarjalainenDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Hui Hao-ShenDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
Anastasiya BörschDepartment of Biomedicine, Bioinformatics, University of Basel and University Hospital Basel, Basel, Switzerland.
Athimed El TaherDepartment of Biomedicine, Bioinformatics, University of Basel and University Hospital Basel, Basel, Switzerland.ORCID 0000-0003-2424-8476
Jessica SchulzInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Jean-Christophe LerouxInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID 0000-0001-5601-1292
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Radek C SkodaDepartment of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-3626-9496
University of Basel · CHETH Zurich · CHSIB Swiss Institute of Bioinformatics · CHInserm · FRUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPegylated interferon alfa (pegIFN-α) can induce molecular remissions in patients with JAK2-V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFN-α. We investigated whether DNMT3A loss leads to alterations in JAK2-V617F LT-HSC functions conferring resistance to pegIFN-α treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long-term treatment with pegIFN-α normalized blood parameters and reduced splenomegaly and JAK2-V617F chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFN-α in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN-α treatment. RNA sequencing showed that IFN-α induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ than from VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFN-α signaling. Transplantations of bone marrow from pegIFN-α-treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFN-α exposure, whereas in patients with JAK2-V617F alone, the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFN-α combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.

Indexed as

DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADrug Resistance, NeoplasmHematopoietic Stem CellsInterferon-alphaJanus Kinase 2Myeloproliferative DisordersAnimalsCell Self RenewalHumansMiceMice, Inbred C57BLPolyethylene GlycolsRecombinant ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanDnmt3a protein, mouseInterferon-alphaJAK2 protein, humanJak2 protein, mouseJanus Kinase 2peginterferon alfa-2aPolyethylene GlycolsRecombinant Proteins

Identifiers

PMID38493481
PMCPMC11208296
OpenAlexW4392892875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.